MX2016010104A - Uso de paricalcitol en el tratamiento de la anemia inflamatoria. - Google Patents
Uso de paricalcitol en el tratamiento de la anemia inflamatoria.Info
- Publication number
- MX2016010104A MX2016010104A MX2016010104A MX2016010104A MX2016010104A MX 2016010104 A MX2016010104 A MX 2016010104A MX 2016010104 A MX2016010104 A MX 2016010104A MX 2016010104 A MX2016010104 A MX 2016010104A MX 2016010104 A MX2016010104 A MX 2016010104A
- Authority
- MX
- Mexico
- Prior art keywords
- paricalcitol
- treatment
- erythropoeisis
- stimulating agents
- inflammatory anaemia
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A61K31/592—9,10-Secoergostane derivatives, e.g. ergocalciferol, i.e. vitamin D2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1816—Erythropoietin [EPO]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
La presente invención describe el uso de paricalcitol, análogo sintético de la vitamina D, en el tratamiento de la anemia inflamatoria, preferentemente en combinación con agentes estimuladores de la eritropoyesis. El uso del paricalcitol para el tratamiento de dicha patología está asociado a un menor requerimiento de agentes estimuladores de la eritropoyesis, a una mejor utilización del hierro y a un incremento en los niveles de eritropoyetina plasmática, por parte de dichos pacientes. La presente invención describe además composiciones farmacéuticas que comprenden paricalcitol en combinación con agentes estimuladores de la eritropoyesis y excipientes farmacéuticamente aceptables, así como el uso de las mismas como medicamentos para el tratamiento de la anemia inflamatoria.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES201430177A ES2472040B1 (es) | 2014-02-11 | 2014-02-11 | Uso de paricalcitol en el tratamiento de la anemia inflamatoria |
| PCT/EP2015/050817 WO2015121022A1 (en) | 2014-02-11 | 2015-01-16 | Use of paricalcitol in the treatment of inflammatory anaemia |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2016010104A true MX2016010104A (es) | 2017-01-06 |
| MX365096B MX365096B (es) | 2019-05-22 |
Family
ID=51205045
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016010104A MX365096B (es) | 2014-02-11 | 2015-01-16 | Uso de paricalcitol en el tratamiento de la anemia inflamatoria. |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US11464791B2 (es) |
| EP (1) | EP3104872B1 (es) |
| JP (1) | JP2017512753A (es) |
| KR (1) | KR20160113664A (es) |
| CN (1) | CN106061498B (es) |
| AR (1) | AR099330A1 (es) |
| AU (1) | AU2015217956B2 (es) |
| CA (1) | CA2938057A1 (es) |
| DK (1) | DK3104872T3 (es) |
| ES (2) | ES2472040B1 (es) |
| IL (1) | IL247207B (es) |
| MX (1) | MX365096B (es) |
| PT (1) | PT3104872T (es) |
| RU (1) | RU2016131412A (es) |
| UY (1) | UY35989A (es) |
| WO (1) | WO2015121022A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102504090B1 (ko) * | 2020-08-05 | 2023-02-24 | 경상국립대학교병원 | 조영제-유발 신독성 예방 또는 치료용 약학 조성물 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1583539A2 (en) | 2003-01-13 | 2005-10-12 | Cedars-Sinai Medical Center | Paricalcitol as a chemotherapeutic agent |
| AU2005235794A1 (en) * | 2004-04-23 | 2005-11-03 | Cambridge Antibody Technology Limited | Erythropoietin protein variants |
| CN101610782A (zh) * | 2007-01-10 | 2009-12-23 | 爱迪生药物公司 | 使用具有促红细胞生成素或血小板生成素活性的化合物治疗呼吸链紊乱 |
| CN102772364B (zh) * | 2011-05-13 | 2015-12-02 | 重庆华邦制药有限公司 | 帕立骨化醇的脂肪乳及其制剂和制备方法 |
-
2014
- 2014-02-11 ES ES201430177A patent/ES2472040B1/es not_active Expired - Fee Related
-
2015
- 2015-01-16 MX MX2016010104A patent/MX365096B/es active IP Right Grant
- 2015-01-16 CN CN201580007824.4A patent/CN106061498B/zh active Active
- 2015-01-16 AU AU2015217956A patent/AU2015217956B2/en active Active
- 2015-01-16 RU RU2016131412A patent/RU2016131412A/ru unknown
- 2015-01-16 DK DK15702156.9T patent/DK3104872T3/da active
- 2015-01-16 JP JP2016552329A patent/JP2017512753A/ja active Pending
- 2015-01-16 WO PCT/EP2015/050817 patent/WO2015121022A1/en not_active Ceased
- 2015-01-16 ES ES15702156T patent/ES2728158T3/es active Active
- 2015-01-16 EP EP15702156.9A patent/EP3104872B1/en active Active
- 2015-01-16 US US15/117,896 patent/US11464791B2/en active Active
- 2015-01-16 PT PT15702156T patent/PT3104872T/pt unknown
- 2015-01-16 KR KR1020167023202A patent/KR20160113664A/ko not_active Ceased
- 2015-01-16 CA CA2938057A patent/CA2938057A1/en not_active Abandoned
- 2015-02-10 AR ARP150100380A patent/AR099330A1/es unknown
- 2015-02-10 UY UY35989A patent/UY35989A/es not_active Application Discontinuation
-
2016
- 2016-08-10 IL IL247207A patent/IL247207B/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| CN106061498B (zh) | 2019-12-06 |
| PT3104872T (pt) | 2019-06-11 |
| ES2472040R1 (es) | 2014-09-18 |
| AU2015217956A1 (en) | 2016-08-25 |
| RU2016131412A (ru) | 2018-03-15 |
| ES2472040B1 (es) | 2015-07-01 |
| EP3104872A1 (en) | 2016-12-21 |
| DK3104872T3 (da) | 2019-06-17 |
| EP3104872B1 (en) | 2019-03-13 |
| CN106061498A (zh) | 2016-10-26 |
| IL247207B (en) | 2020-02-27 |
| IL247207A0 (en) | 2016-09-29 |
| MX365096B (es) | 2019-05-22 |
| ES2728158T3 (es) | 2019-10-22 |
| JP2017512753A (ja) | 2017-05-25 |
| US20160367571A1 (en) | 2016-12-22 |
| ES2472040A2 (es) | 2014-06-27 |
| US11464791B2 (en) | 2022-10-11 |
| WO2015121022A1 (en) | 2015-08-20 |
| KR20160113664A (ko) | 2016-09-30 |
| AR099330A1 (es) | 2016-07-13 |
| UY35989A (es) | 2015-03-27 |
| AU2015217956B2 (en) | 2019-04-04 |
| CA2938057A1 (en) | 2015-08-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY191574A (en) | Pharmaceutical compositions comprising meloxicam | |
| PH12021551189A1 (en) | Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo | |
| IN2013MU01696A (es) | ||
| IN2014MU00303A (es) | ||
| PH12016501841A1 (en) | Immunosuppressant formulation | |
| NZ744323A (en) | Compositions comprising 15-hepe and methods of using the same | |
| IN2013MU00711A (es) | ||
| MX2018005358A (es) | Comprimido de dosis alta que contiene mesalazina optimizado. | |
| CY1119532T1 (el) | (s)-πιρλινδολη και τα φαρμακευτικως αποδεκτα αλατα αυτης για χρηση στην ιατρικη | |
| MX2016015261A (es) | Dispersion solida de allisartan isoproxilo y su composicion. | |
| PH12016502236A1 (en) | (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine | |
| MX2018015363A (es) | Metodos y composiciones para el tratamiento de la enfermedad celiaca, de la sensibilidad al gluten no celiaca y de la enfermedad celiaca refractaria. | |
| PH12016502480A1 (en) | Compounds, pharmaceutical composition and their use in treating neurodegenerative diseases | |
| MX2017014301A (es) | Composiciones y metodos para el tratamiento o prevencion de hipertension pulmonar. | |
| MX2016010104A (es) | Uso de paricalcitol en el tratamiento de la anemia inflamatoria. | |
| MX2017008931A (es) | Formulaciones farmaceuticas de xantina o derivados de xantina. | |
| NZ739679A (en) | Cholecalciferol sulfate salts and their use for the treatment of vitamin d deficiency | |
| MX2019008847A (es) | Profarmacos de cisteamina. | |
| IN2013MU02015A (es) | ||
| IN2014MU00077A (es) | ||
| IN2014CH00035A (es) | ||
| IN2014CH01195A (es) | ||
| IN2014DE00822A (es) | ||
| MX2012000360A (es) | Combinacion de un atiinflamatorio no esteroideo y un antiespasmodico. | |
| IN2014DE00818A (es) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |